Jeffrey P. Solzak

926 total citations
17 papers, 392 citations indexed

About

Jeffrey P. Solzak is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Jeffrey P. Solzak has authored 17 papers receiving a total of 392 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Molecular Biology and 5 papers in Cancer Research. Recurrent topics in Jeffrey P. Solzak's work include Myasthenia Gravis and Thymoma (4 papers), HER2/EGFR in Cancer Research (4 papers) and Cancer Genomics and Diagnostics (4 papers). Jeffrey P. Solzak is often cited by papers focused on Myasthenia Gravis and Thymoma (4 papers), HER2/EGFR in Cancer Research (4 papers) and Cancer Genomics and Diagnostics (4 papers). Jeffrey P. Solzak collaborates with scholars based in United States, Israel and United Kingdom. Jeffrey P. Solzak's co-authors include Milan Radovich, Bradley A. Hancock, Kathy D. Miller, Randall J. Roper, Dumitru Brinza, Charles Scafe, Laura G. Reinholdt, Anne Czechanski, Yueming Ding and Leah Rae Donahue and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Jeffrey P. Solzak

16 papers receiving 390 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jeffrey P. Solzak United States 8 167 124 117 108 79 17 392
Judith M. de Bont Netherlands 9 236 1.4× 58 0.5× 81 0.7× 25 0.2× 28 0.4× 11 376
Yu‐Chia Chen Taiwan 10 265 1.6× 87 0.7× 208 1.8× 20 0.2× 29 0.4× 23 465
Andrew L. Hong United States 11 231 1.4× 105 0.8× 89 0.8× 20 0.2× 48 0.6× 28 402
Yangyiran Xie United States 10 191 1.1× 77 0.6× 113 1.0× 46 0.4× 9 0.1× 20 380
J. Racquel Collins-Underwood United States 5 283 1.7× 77 0.6× 55 0.5× 234 2.2× 32 0.4× 7 571
Alessandra Franzoni Italy 11 166 1.0× 60 0.5× 63 0.5× 20 0.2× 53 0.7× 33 307
Fredrik Stiger Sweden 12 235 1.4× 126 1.0× 38 0.3× 14 0.1× 135 1.7× 13 436
Federica Zanardi Italy 7 255 1.5× 97 0.8× 74 0.6× 16 0.1× 33 0.4× 7 491
Judd W. Moul United States 10 193 1.2× 90 0.7× 61 0.5× 12 0.1× 38 0.5× 13 476
Hironobu Sasano Japan 10 126 0.8× 60 0.5× 36 0.3× 19 0.2× 85 1.1× 19 333

Countries citing papers authored by Jeffrey P. Solzak

Since Specialization
Citations

This map shows the geographic impact of Jeffrey P. Solzak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey P. Solzak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey P. Solzak more than expected).

Fields of papers citing papers by Jeffrey P. Solzak

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey P. Solzak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey P. Solzak. The network helps show where Jeffrey P. Solzak may publish in the future.

Co-authorship network of co-authors of Jeffrey P. Solzak

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey P. Solzak. A scholar is included among the top collaborators of Jeffrey P. Solzak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey P. Solzak. Jeffrey P. Solzak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Sledge, George W., Joanne Xiu, Jeffrey P. Solzak, et al.. (2025). Comparison of trastuzumab deruxtecan and sacituzumab govitecan in HER2-negative metastatic breast cancer: a large real-world data analysis. Breast Cancer Research. 27(1). 144–144.
2.
Radovich, Milan, Jeffrey P. Solzak, Bradley A. Hancock, et al.. (2022). Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer. Clinical Cancer Research. 28(15). 3235–3241. 21 indexed citations
3.
Radovich, Milan, Sandra K. Althouse, Hao Liu, et al.. (2022). A phase II study of buparlisib in relapsed or refractory thymomas. Frontiers in Oncology. 12. 891383–891383. 10 indexed citations
4.
Radovich, Milan, Jeffrey P. Solzak, Bradley A. Hancock, et al.. (2021). Abstract PS10-26: An initial safety study of gedatolisib plus cofetuzumab pelidotin for metastatic triple-negative breast cancer. Cancer Research. 81(4_Supplement). PS10–26. 1 indexed citations
5.
6.
7.
Solzak, Jeffrey P., et al.. (2020). Abstract P3-10-12: Targeting a common drug compensation pathway using NUPR1 inhibition in triple negative breast cancer. Cancer Research. 80(4_Supplement). P3–10. 1 indexed citations
8.
Hancock, Bradley A., Jeffrey P. Solzak, David C. Wedge, et al.. (2019). Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers. Breast Cancer Research. 21(1). 87–87. 23 indexed citations
9.
Hancock, Bradley A., et al.. (2019). Abstract 2280: Co-detection of circulating tumor DNA and RNA in the plasma of patients with breast cancer increases the detectable number of mutated molecules. Cancer Research. 79(13_Supplement). 2280–2280. 1 indexed citations
10.
Radovich, Milan, Sandra K. Althouse, Hai Liu, et al.. (2018). A phase II study of BKM120 (buparlisib) in relapsed or refractory thymomas.. Journal of Clinical Oncology. 36(15_suppl). e20580–e20580. 3 indexed citations
11.
Hancock, Bradley A., Jeffrey P. Solzak, Dumitru Brinza, et al.. (2017). Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy. npj Breast Cancer. 3(1). 24–24. 93 indexed citations
12.
Solzak, Jeffrey P., Bradley A. Hancock, Anthony L. Sinn, et al.. (2017). Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer. npj Breast Cancer. 3(1). 17–17. 43 indexed citations
13.
Radovich, Milan, Jeffrey P. Solzak, Bradley A. Hancock, et al.. (2016). A large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type A and AB thymomas. PMC. 3 indexed citations
14.
Radovich, Milan, Jeffrey P. Solzak, Bradley A. Hancock, et al.. (2016). A large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type A and AB thymomas. British Journal of Cancer. 114(4). 477–484. 41 indexed citations
15.
Solzak, Jeffrey P., et al.. (2015). Abstract 5340: Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple-negative breast cancer. Cancer Research. 75(15_Supplement). 5340–5340. 1 indexed citations
16.
Solzak, Jeffrey P., Yun Liang, Feng Zhou, & Randall J. Roper. (2013). Commonality in Down and fetal alcohol syndromes. Birth Defects Research Part A Clinical and Molecular Teratology. 97(4). 187–197. 11 indexed citations
17.
Reinholdt, Laura G., Yueming Ding, Anne Czechanski, et al.. (2011). Molecular characterization of the translocation breakpoints in the Down syndrome mouse model Ts65Dn. Mammalian Genome. 22(11-12). 685–691. 138 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Judith M. de Bont Breakdown of academic impact, for papers by Yu‐Chia Chen Breakdown of academic impact, for papers by Andrew L. Hong Breakdown of academic impact, for papers by Yangyiran Xie Breakdown of academic impact, for papers by J. Racquel Collins-Underwood Breakdown of academic impact, for papers by Alessandra Franzoni Breakdown of academic impact, for papers by Fredrik Stiger Breakdown of academic impact, for papers by Federica Zanardi Breakdown of academic impact, for papers by Judd W. Moul Breakdown of academic impact, for papers by Hironobu Sasano
Rankless by CCL
2026